Scienture
Scienture is a U.S. specialty pharmaceutical company that develops and commercializes FDA-approved formulations—including Arbli (liquid losartan) and REZENOPY (high-dose naloxone nasal spray)—for cardiovascular and CNS indications, serving healthcare institutions and patients through wholesalers and GPO networks.
- Company typePublic
- Founded2019
- HeadquartersHauppauge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Scienture does
Scienture Holdings, Inc. (NASDAQ: SCNX) is a U.S.-based specialty pharmaceutical company that develops and commercializes differentiated formulations in cardiovascular and central nervous system (CNS) therapeutics. Through its operating subsidiary Scienture LLC (Commack, New York), the company has secured two FDA approvals: Arbli (losartan potassium oral suspension, 10 mg/mL), the first FDA-approved ready-to-use liquid losartan for hypertension, diabetic nephropathy, and stroke risk reduction; and REZENOPY (naloxone HCl nasal spray, 10 mg), the highest-strength FDA-approved naloxone nasal spray in the U.S. for emergency opioid overdose treatment. A pipeline of three early-stage candidates (SCN-104, SCN-106, SCN-107) targets additional CNS/pain and cardiovascular indications.
The business model combines direct commercial sales through major U.S. wholesalers and GPO networks (covering over 5,000 healthcare institutions and approximately 60% of the U.S. institutional naloxone market) with exclusive commercial licensing partnerships—most notably with Kindeva Drug Delivery for REZENOPY (signed March 2025) and co-development with Summit Biosciences Inc. REZENOPY is protected by a U.S. patent running through 2041. Arbli has been added to formularies of major national health plans covering over 100 million lives.
The company is in early commercial stages: Arbli became commercially available in October 2025 and REZENOPY is targeted for early Q2 2026 launch. Scienture went public on NASDAQ and is currently operating under a 180-day compliance extension (until October 12, 2026) to meet the minimum bid price requirement. Founder and CEO Shankar Hariharan leads the company, which maintains a lean 1–10 person headcount and has raised $6 million in funding as of December 2020.
Scienture firmographics
Firmographics- Name
- Scienture
- Legal name
- Scienture, LLC
- Website
- https://scienture.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Scienture is a U.S. specialty pharmaceutical company that develops and commercializes FDA-approved formulations—including Arbli (liquid losartan) and REZENOPY (high-dose naloxone nasal spray)—for cardiovascular and CNS indications, serving healthcare institutions and patients through wholesalers and GPO networks.
- Ownership category
- akta.pro rank
Scienture industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
Keywords
Where Scienture is headquartered
LocationHeadquarters
- HQ city
- Hauppauge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Scienture business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Product Sales: Revenue generated from commercial sales of FDA-approved pharmaceutical products including Arbli (losartan potassium oral suspension) and REZENOPY (naloxone HCl nasal spray) distributed through wholesalers and healthcare institutions.
- Licensing and Commercial Agreements: Revenue from exclusive commercial license agreements for pharmaceutical products, including collaboration with Summit Biosciences Inc. and Kindeva Drug Delivery for development and commercialization rights.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Scienture product offering
Product offeringCore offering
Scienture develops and commercializes specialty pharmaceutical products targeting cardiovascular and central nervous system diseases through differentiated drug delivery formats. Its commercial portfolio includes Arbli, the first FDA-approved ready-to-use oral liquid losartan for hypertension, and REZENOPY, the highest strength FDA-approved naloxone HCl nasal spray for opioid overdose reversal. The company also maintains an early-stage pipeline of CNS/pain and cardiovascular candidates.
Product overview
Scienture is a specialty pharmaceutical company focused on developing and commercializing differentiated products for cardiovascular and central nervous system diseases. The portfolio consists of two FDA-approved commercial products—Arbli™ (losartan potassium oral suspension) for hypertension treatment and REZENOPY™ (naloxone HCl nasal spray) for emergency opioid overdose treatment—alongside a pipeline of three early-stage candidates (SCN-104, SCN-106, SCN-107) targeting CNS/pain and cardiovascular indications.
Differentiator
Problem solved
Functional benefit
Brands
- Arbli: FDA-approved oral liquid losartan potassium (10 mg/mL) for cardiovascular use, specifically for treating hypertension.
- REZENOPY
Products and services
- Arbli (losartan potassium) oral suspension FDA-approved ready-to-use oral liquid formulation of losartan potassium (10 mg/mL) for treating hypertension, diabetic nephropathy, and reducing stroke risk in patients—including those with dysphagia or difficulty swallowing solid oral medications. First commercially available FDA-approved oral liquid losartan for cardiovascular use.
- REZENOPY (naloxone HCl) nasal spray 10 mg FDA-approved high-dose naloxone HCl nasal spray (10 mg) for emergency opioid overdose treatment. The highest strength and most potent FDA-approved naloxone nasal spray on the U.S. market, designed to address overdose situations involving potent synthetic opioids.
Quantifiable outcome
- Access to over 100 million covered lives through formulary additions
- +1 more outcomes
Companies that use Scienture
Customer profileSegments3 records
Ideal customer profiles2 records
Scienture technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Scienture partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Summit Biosciences Inc.coreCollaboration with Summit Biosciences Inc. for the development of REZENOPY (Naloxone HCl) Nasal Spray 10 mg. This partnership led to U.S. patent protection effective through 2041, following FDA approval in 2024.
- Kindeva Drug DeliverycoreExclusive commercial license agreement for REZENOPY (naloxone HCl nasal spray 10mg) entered into in March 2025, enabling commercialization of the FDA-approved opioid overdose treatment product.
- Major U.S. WholesalerscoreProduct distribution partnerships with major U.S. wholesalers for commercial availability of Arbli, providing broad market access for the hypertension treatment product.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Scienture competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Scienture social profiles
Digital presenceScienture financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scienture leadership team
Management profileNumber of profiles
Profiles1 record
Scienture subsidiaries and ownership
Company hierarchySubsidiaries1 record
Scienture funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scienture M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scienture
What does Scienture do?
Scienture develops and commercializes specialty pharmaceutical products targeting cardiovascular and central nervous system diseases through differentiated drug delivery formats. Its commercial portfolio includes Arbli, the first FDA-approved ready-to-use oral liquid losartan for hypertension, and REZENOPY, the highest strength FDA-approved naloxone HCl nasal spray for opioid overdose reversal. The company also maintains an early-stage pipeline of CNS/pain and cardiovascular candidates.
Is Scienture a public or private company?
Scienture is a public company. It is classified as public and is currently operating.
When was Scienture founded?
Scienture was founded in 2019. It employs 1 to 10 people.
Where is Scienture based?
Scienture is headquartered in Hauppauge, United States, in the North America region.
How does Scienture make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Commercial Agreements.
Does Scienture have an API?
No public API is recorded for Scienture.
What industry is Scienture in?
Scienture's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.